The Assign Group Selects Oracle® Health Sciences Applications to Support Expansion Strategy

The Assign Group Selects Oracle® Health Sciences Applications to Support Expansion Strategy
Full-Service, Europe-based Contract Research Organization to Standardize Clinical Trial and Clinical Data Management on Oracle Health Sciences Platform
Redwood Shores, CA - October 21, 2009
News Facts
The Assign Group, a contract research organization that provides clinical trial and clinical trial data management through a network of affiliates in Europe and South America, is standardizing on Oracle® Health Sciences applications to gain scalability and robust functionality and streamline IT vendor management by selecting a single source for clinical applications across the group.
Assign Data Management & Biostatistics GmbH, the group's affiliate that specializes in clinical trial data management, biostatistics and pharmacovigilance, has selected Oracle Clinical, Oracle Remote Data Capture, Oracle Adverse Event Reporting System and Oracle Thesaurus Management System as the foundation for a robust and standards-based clinical data management infrastructure that will support higher data volumes and an increased number of trials conducted in a broad range of clinical settings. The applications also will facilitate data export.
In addition, the group's affiliates responsible for managing clinical trial processes are migrating to Oracle's Siebel Clinical Trial Management System to enable greater visibility and management efficiency.
The Assign Group wanted an industry-proven, commercial off-the-shelf (COTS) solution that would further credential the organization in the market and enable it to focus resources on its core business, instead of on building and maintaining complex IT systems to support business processes across all affiliates.
The company plans to go live with all applications later this year. It is working with Triumph Consulting and Pharmasol, both Oracle Certified Partners, and is using Pharmasol RapidLive - an Oracle Accelerate solution that provides ready-to-use and validated implementations of Oracle Health Sciences applications - to accelerate the deployment cycle.
Supporting Quotes
"Oracle's Siebel Clinical Trial Management System, Oracle Clinical and Oracle Remote Data Capture Onsite deliver powerful functionality and the scalability we require to grow our business. As important, they are industry-proven and respected solutions that will provide us with a key selling point in our discussions with potential clients," said Dr. Anton Klingler, General Manager, Assign Data Management & Biostatistics GmbH.
"Health sciences organizations, like The Assign Group, are increasingly looking to IT solutions to help streamline clinical data management and improve efficiency throughout the clinical trial process," said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. "Oracle delivers a comprehensive suite of clinical IT applications with unmatched functionality - enabling organizations to address complex business challenges and accelerate insights for better health."
Supporting Resources
About The Assign Group
Market Research Firm Cites Oracle as Top Software Vendor for the Life Sciences Industry
Follow Oracle Health Sciences on TwitterJoin the Oracle Health Sciences Community on FacebookOracle in Health SciencesAbout Oracle
Oracle (NASDAQ: ORCL) is the world's largest business software company. For more information about Oracle, please visit our Web site at http://www.oracle.com.

Trademarks
Oracle is a registered trademark of Oracle Corporation and/or its affiliates. Other names may be trademarks of their respective owners.
Contact Info

Kevin Ruane
Oracle
+1.650.506.6610
[email protected]

  
Oracle 1-800-633-0738
Oracle Media Relations
Global contactsExpand All | Close AllRSSSubscribe 
Find out more about RSS
NewslettersNews, articles, offers, and more, for Oracle technology, applications, industries, and solutions.Subscribe

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.